Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Avistone’s Met challenge
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Corvus goes pivotal in peripheral T-cell lymphoma
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
A new order in BTK inhibition
Imbruvica faces challenges on multiple fronts.
ASH 2023 movers – an unexpected comeback for MorphoSys
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
ASH 2023 – sense and serendipity in Dizal's Jackpot win
Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.
